Evidence map›Paper›PMID 31775818›Full record

ArticleJournal of orthopaedic surgery and research2019

Effect of sIL-13Rα2-Fc on the progression of rat tail intervertebral disc degeneration.

Xin Wang, Junhao Sun, Jianshi Tan, Pengzhong Fang, Jinlei Chen, Wen Yuan, Huajiang Chen, Yang Liu

Open access · goldAbstract read
In one paragraph

Article in Journal of orthopaedic surgery and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xin WangDepartment of Orthopedics, First Clinical Medical College of Lanzhou University, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China. wangxinldyy@126.com.ORCID http://orcid.org/0000-0002-0728-6166
Junhao SunDepartment of Orthopedics, First Clinical Medical College of Lanzhou University, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China.
Jianshi TanDepartment of Orthopedics, First Clinical Medical College of Lanzhou University, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China.
Pengzhong FangDepartment of Orthopedics, First Clinical Medical College of Lanzhou University, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China.
Jinlei ChenDepartment of Orthopedics, First Clinical Medical College of Lanzhou University, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China.
Wen YuanChangzheng Orthopedics Hospital, Second Military Medical University, Shanghai, 200003, China.
Huajiang ChenChangzheng Orthopedics Hospital, Second Military Medical University, Shanghai, 200003, China.
Yang LiuChangzheng Orthopedics Hospital, Second Military Medical University, Shanghai, 200003, China. liuyangspine1@hotmail.com.
First Hospital of Lanzhou University · CNSecond Military Medical University · CN

Funding

China Postdoctoral Science Foundation No. 2017M613342Gansu Natural Science Foundation No.18JR3RA353Lanzhou Chengguan Science and Technology Bureau No. 2017SHFZ0036The first hospital of Lanzhou University Foundation No.ldyyyn2017-26
6 · The paper itself

Abstract

backgroundThe incidence of degenerative disc disease caused by intervertebral disc injury is increasing annually, seriously affecting the quality of life of patients and increasing the disease burden on society. The mechanisms of intervertebral disc degeneration include changes in extracellular matrix (ECM) deposition and tissue fibrosis. sIL-13Rα2-Fc potently inhibits interleukin (IL)-13, as well as blocks related cell signaling pathways and inhibits fibrosis in certain tissues. However, it is unknown whether sIL-13Rα2-Fc inhibits fibrosis in injured intervertebral discs and slows the process of degeneration. We hypothesized that sIL-13Rα2-Fc delays the progression of intervertebral disc degeneration by inhibiting intervertebral disc fibrosis and improving ECM deposition.

methodsA rat tail intervertebral disc degeneration model was established. Pathological changes in rat intervertebral disc tissue were observed by hematoxylin and eosin staining and Masson staining. Glycosaminoglycan (GAG), chondroitin sulfate (CS), keratan sulfate (KS), and hyaluronic acid (HA) contents were quantitatively analyzed by enzyme-linked immunosorbent assay. Type I and type II collagen expression levels were analyzed by reverse transcription-PCR and western blotting.

resultsHematoxylin and eosin staining and Masson staining revealed annulus fibrosus rupture, disordered arrangement, decreased nucleus pulposus tissue, and decreased collagen fiber in the rat intervertebral disc tissue. Following treatment with sIL-13Rα2-Fc, pathological changes in the rat intervertebral disc were reduced. Rat intervertebral disc tissue showed decreased GAG, CS-KS, and (HA) contents, increased type I collagen levels, and decreased type II collagen levels in degenerated intervertebral discs. sIL-13Rα2-Fc intervention increased the contents of GAG, CS, KS, and HA; inhibited the expression of type I collagen; and promoted the expression of type II collagen.

conclusionThese results demonstrate that intervertebral disc degeneration is associated with tissue fibrosis. sIL-13Rα2-Fc can regulate type I and type II collagen expression levels by increasing GAG, CS, KS, and HA contents, thereby slowing the progression of intervertebral disc degeneration.

Indexed as

AnimalsDrug Evaluation, PreclinicalImmunoglobulin Fc FragmentsInterleukin-13 Receptor alpha2 SubunitIntervertebral DiscIntervertebral Disc DegenerationRats, Sprague-DawleyTailImmunoglobulin Fc FragmentsInterleukin-13 Receptor alpha2 SubunitCollagenFibrosisIntervertebral disc degenerationsIL-13Rα2

Identifiers

PMID31775818
PMCPMC6880576
OpenAlexW2989625451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.